Viatris Gains FDA Approval for RYZUMVI® as Acquisition of Pacira BioSciences Advances

This week brought two material developments for Viatris Inc. (NASDAQ: VTRS) that are poised to reshape its strategic direction and product portfolio.

FDA Approval of RYZUMVI® for Presbyopia

On October 16, 2026, the U.S. Food and Drug Administration granted approval for RYZUMVI® (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults. Previously approved for pharmacologically induced mydriasis, RYZUMVI® now gains a new indication addressing age-related near-vision decline.

This approval expands Viatris’s ophthalmology portfolio and adds a novel therapeutic option for the millions of adults experiencing blurred near vision. The FDA’s decision represents a key pipeline advancement for the company in 2026.

Acquisition of Pacira BioSciences in $1.65 Billion Cash Deal

On October 8, 2026, Viatris entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $36.50 per share in cash, representing an aggregate equity value of approximately $1.65 billion.

Pacira brings two patented, high-margin, commercially available products—EXAPREL® (bupivacaine liposome injectable suspension) and ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)—strengthening Viatris’s position in non‑opioid pain therapies. The deal is expected to close by the end of 2026 and to be immediately accretive to Viatris’s financial guidance metrics.

Company leadership highlighted the acquisition’s strategic fit, noting it boosts U.S. innovative medicines commercialization and R&D capabilities, and aligns with Viatris’s capital allocation discipline.

Stock Price Context

VTRS shares closed on October 23, 2026, at $18.00, reflecting a 1.8% decline for the day. The movements occurred amid growing investor focus on the RYZUMVI® approval and Pacira acquisition.

While daily trading reflects these developments, it remains premature to attribute the price change to either event directly, without supportive financial reporting linking specific headlines to share performance.

Why This Matters

These back‑to‑back developments mark a pivotal inflection point for Viatris. The RYZUMVI® approval signals progress in the company’s ambitious specialty pipeline, while the Pacira acquisition accelerates its strategic pivot into non-opioid pain management. Combined, they strengthen both product breadth and long-term growth potential.

Investors may now monitor the following catalysts:

• Potential early 2027 commercialization plans and U.S. launch strategy for RYZUMVI®.
• Regulatory or shareholder milestones associated with the Pacira acquisition and integration execution.
• Upcoming Q3 2026 earnings results, scheduled for November 5, 2026, which could clarify financial impact from both developments.